PL2235007T3 - Niesteroidowi antagoniści receptora mineralokortykoidowego pochodzący od 6H-dibenzo[B,E]oksepiny - Google Patents

Niesteroidowi antagoniści receptora mineralokortykoidowego pochodzący od 6H-dibenzo[B,E]oksepiny

Info

Publication number
PL2235007T3
PL2235007T3 PL08866835T PL08866835T PL2235007T3 PL 2235007 T3 PL2235007 T3 PL 2235007T3 PL 08866835 T PL08866835 T PL 08866835T PL 08866835 T PL08866835 T PL 08866835T PL 2235007 T3 PL2235007 T3 PL 2235007T3
Authority
PL
Poland
Prior art keywords
dibenz0
oxepine
receptor antagonists
mineralocorticoid receptor
derived
Prior art date
Application number
PL08866835T
Other languages
English (en)
Inventor
Konstantinos Gavardinas
Prabhakar Kondaji Jadhav
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40430143&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2235007(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PL2235007T3 publication Critical patent/PL2235007T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
PL08866835T 2007-12-19 2008-12-09 Niesteroidowi antagoniści receptora mineralokortykoidowego pochodzący od 6H-dibenzo[B,E]oksepiny PL2235007T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1477607P 2007-12-19 2007-12-19
PCT/US2008/085997 WO2009085584A1 (en) 2007-12-19 2008-12-09 6h-dibenz0 [b, e] oxepine derived nonsteroidal mineralocorticoid receptor antagonists
EP08866835A EP2235007B1 (en) 2007-12-19 2008-12-09 6h-dibenz0 [b, e] oxepine derived nonsteroidal mineralocorticoid receptor antagonists

Publications (1)

Publication Number Publication Date
PL2235007T3 true PL2235007T3 (pl) 2013-03-29

Family

ID=40430143

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08866835T PL2235007T3 (pl) 2007-12-19 2008-12-09 Niesteroidowi antagoniści receptora mineralokortykoidowego pochodzący od 6H-dibenzo[B,E]oksepiny

Country Status (33)

Country Link
US (1) US7994164B2 (pl)
EP (2) EP2235007B1 (pl)
JP (1) JP5562866B2 (pl)
KR (1) KR101254382B1 (pl)
CN (1) CN101903377B (pl)
AR (1) AR069554A1 (pl)
AU (1) AU2008343524B2 (pl)
BR (1) BRPI0820805A2 (pl)
CA (1) CA2710409C (pl)
CL (1) CL2008003600A1 (pl)
CO (1) CO6300953A2 (pl)
DK (1) DK2235007T3 (pl)
DO (1) DOP2010000185A (pl)
EA (1) EA017668B1 (pl)
EC (2) ECSP10010266A (pl)
ES (2) ES2396605T3 (pl)
GT (1) GT201000179A (pl)
HR (1) HRP20120916T1 (pl)
IL (1) IL206353A (pl)
MA (1) MA31910B1 (pl)
MX (1) MX2010006911A (pl)
MY (1) MY150474A (pl)
NZ (1) NZ586300A (pl)
PE (1) PE20091057A1 (pl)
PL (1) PL2235007T3 (pl)
PT (1) PT2235007E (pl)
RS (1) RS52594B (pl)
SI (1) SI2235007T1 (pl)
TN (1) TN2010000292A1 (pl)
TW (1) TWI431010B (pl)
UA (1) UA100131C2 (pl)
WO (1) WO2009085584A1 (pl)
ZA (1) ZA201004257B (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2188274A4 (en) 2007-08-03 2011-05-25 Boehringer Ingelheim Int VIRAL POLYMERASE HEMMER
WO2009076747A1 (en) 2007-12-19 2009-06-25 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
JP5570536B2 (ja) * 2009-03-12 2014-08-13 イーライ リリー アンド カンパニー 鉱質コルチコイド受容体アンタゴニストおよび使用方法
CA2796307A1 (en) 2010-05-10 2011-11-17 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for the treatment of fluid accumulation in and/ or under the retina
JP6180930B2 (ja) 2010-06-16 2017-08-16 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 創傷治癒過程における再上皮化を刺激するための方法及び組成物
CN102060670A (zh) * 2011-01-04 2011-05-18 常州大学 一种2-溴-6-氟苯甲醇的制备方法
AP2015008843A0 (en) 2013-05-02 2015-11-30 Pfizer Imidazo-triazine derivatives as pde10 inhibitors
AR099416A1 (es) 2014-02-28 2016-07-20 Lilly Co Eli Terapia combinada para la hipertensión resistente
SI3160948T1 (sl) 2014-06-30 2020-06-30 Astrazeneca Ab Amidi benzoksazinona, kot modulatorji receptorja mineralokortikoida
CA2963683A1 (en) * 2014-11-21 2016-05-26 Eli Lilly And Company 1,2-benzothiazole compounds for the treatment of kidney disorders
US20180280414A1 (en) 2015-10-13 2018-10-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation
EP3490606B8 (en) 2016-07-26 2024-04-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis
MX391602B (es) * 2016-09-24 2025-03-21 Novo Nordisk As Composicion farmaceutica con antagonista del receptor de mineralocorticoides y su uso
WO2021180818A1 (en) 2020-03-11 2021-09-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of determining whether a subject has or is at risk of having a central serous chorioretinopathy
WO2023031277A1 (en) 2021-08-31 2023-03-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of ocular rosacea

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4072756A (en) 1973-05-17 1978-02-07 Sandoz Ltd. Tricyclo piperidino ketones and soporific compositions thereof
SE426341C (sv) * 1980-02-14 1985-09-23 Fagersta Ab Sett att forhindra korrosion i en forbrenningsanleggnings kylare och skorsten vid kylning av rokgaser
DE3730258A1 (de) 1986-09-10 1988-04-07 Canon Kk Elektrophotographisches lichtempfindliches aufzeichnungsmaterial, 5h-dibenzo(a,d)cycloheptanylidenderivat, 5h-dibenzo(a,d)cycloheptenylidenderivat und verfahren zu ihrer herstellung
US4999363A (en) 1988-06-09 1991-03-12 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds
GB8914061D0 (en) 1989-06-19 1989-08-09 Wellcome Found Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
US5378701A (en) 1991-12-27 1995-01-03 Kyowa Hakko Kogyo Tricyclic compounds
ZA9811898B (en) 1997-12-29 2000-06-28 Ortho Mcneil Pharm Inc Anti-Inflammatory Compounds.
EP1154997A4 (en) 1999-01-26 2002-11-04 Dana Farber Cancer Inst Inc PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE
EP1448566B3 (en) * 2001-11-21 2009-04-08 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use thereof
TW200400816A (en) * 2002-06-26 2004-01-16 Lilly Co Eli Tricyclic steroid hormone nuclear receptor modulators
ES2308296T3 (es) 2003-12-19 2008-12-01 Eli Lilly And Company Modulares del receptor nuclear de hormonas esteroideas triciclicas.
WO2005066153A1 (en) 2003-12-19 2005-07-21 Eli Lilly And Company Tricyclic steroid hormone nuclear receptor modulators
TWI350168B (en) 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
JP2008508314A (ja) 2004-07-28 2008-03-21 アイアールエム・リミテッド・ライアビリティ・カンパニー ステロイドホルモン核内受容体のモジュレーターとしての化合物および組成物
KR101368228B1 (ko) 2004-11-10 2014-02-27 인사이트 코포레이션 락탐 화합물 및 약제로서의 이의 용도
AP2527A (en) 2006-10-31 2012-12-06 Pfizer Prod Inc Pyrazoline compounds as mineralocorticoid receptorantagonists
EP2142194A1 (en) 2007-03-29 2010-01-13 N.V. Organon Mineralocorticoid receptor antagonists
GB0725102D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
PE20091339A1 (es) 2007-12-21 2009-09-26 Glaxo Group Ltd Derivados de oxadiazol con actividad sobre receptores s1p1
CA2711887A1 (en) 2008-01-25 2009-07-30 Arena Pharmaceuticals, Inc. Dihydro-1h-pyrrolo [1,2-a] indol-1-yl carboxylic derivatives which act as s1p1 agonists
JP5570536B2 (ja) 2009-03-12 2014-08-13 イーライ リリー アンド カンパニー 鉱質コルチコイド受容体アンタゴニストおよび使用方法

Also Published As

Publication number Publication date
SI2235007T1 (sl) 2013-01-31
ES2459318T3 (es) 2014-05-09
KR20100082866A (ko) 2010-07-20
MX2010006911A (es) 2010-10-05
ECSP12012048A (es) 2012-08-31
CA2710409C (en) 2012-11-06
US20090163472A1 (en) 2009-06-25
AU2008343524A1 (en) 2009-07-09
CA2710409A1 (en) 2009-07-09
IL206353A (en) 2014-06-30
TW200930721A (en) 2009-07-16
EA017668B1 (ru) 2013-02-28
CN101903377A (zh) 2010-12-01
ZA201004257B (en) 2011-11-30
JP2011507868A (ja) 2011-03-10
EP2537845A1 (en) 2012-12-26
EP2537845B1 (en) 2014-03-19
GT201000179A (es) 2012-04-16
TN2010000292A1 (en) 2011-11-11
US7994164B2 (en) 2011-08-09
PT2235007E (pt) 2013-01-22
RS52594B (sr) 2013-04-30
EA201070762A1 (ru) 2010-12-30
UA100131C2 (uk) 2012-11-26
NZ586300A (en) 2012-06-29
TWI431010B (zh) 2014-03-21
MA31910B1 (fr) 2010-12-01
KR101254382B1 (ko) 2013-04-15
DK2235007T3 (da) 2012-12-17
WO2009085584A1 (en) 2009-07-09
CN101903377B (zh) 2014-07-09
JP5562866B2 (ja) 2014-07-30
AU2008343524B2 (en) 2012-03-08
MY150474A (en) 2014-01-30
IL206353A0 (en) 2010-12-30
HRP20120916T1 (hr) 2012-12-31
PE20091057A1 (es) 2009-07-20
CL2008003600A1 (es) 2010-02-19
DOP2010000185A (es) 2010-09-15
AR069554A1 (es) 2010-02-03
EP2235007A1 (en) 2010-10-06
HK1144284A1 (en) 2011-02-11
CO6300953A2 (es) 2011-07-21
ES2396605T3 (es) 2013-02-22
BRPI0820805A2 (pt) 2015-06-16
EP2235007B1 (en) 2012-10-31
ECSP10010266A (es) 2010-07-30

Similar Documents

Publication Publication Date Title
PT2235007E (pt) Antagonistas não esteróides do receptor de mineralocorticóides derivados de 6h-dibenzo[b,e]oxepina
EP2184278A4 (en) P2X4 RECEIVER ANTAGONIST
EP2058304A4 (en) P2X4 RECEPTOR ANTAGONIST
PT1981902E (pt) Antagonistas dos recetores nogo
ZA201104706B (en) Substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds
ZA200705449B (en) 2-phenyl-indoles as prostaglandin D2 receptor antagonists
IL188478A0 (en) Indol-3-carbonyl-spiro-piperidine derivatives as v1a receptor antagonists
ZA200906812B (en) Crig antagonists
IL196587A0 (en) 2-phenyl-indoles as prostaglandin d2 receptor antagonists
GB0509275D0 (en) Synthetic receptor
ZA201000676B (en) Pyrrolidine aryl-ether as NK3 receptor antagonists
ZA201001125B (en) Pyrrolidine Aryl-Ether as NK3 receptor antagonists
GB0717233D0 (en) Traffic monitoring
EP2191830A4 (en) SOLID PREPARATION COMPRISING A NPYY5 RECEPTOR ANTAGONIST
IL198542A0 (en) 2-aminoquinolines as 5-ht(5a)receptor antagonists
EP2153736A4 (en) NEW LEUKOTRIEN RECEPTOR ANTAGONIST
EP2222676A4 (en) A1-adenosine receptor antagonistic
IL207700A0 (en) 3-aminoalkyl-1,4-diazepan-2-one melanocortin -5 receptor antagonists
PT1912976E (pt) Derivados de indol-3-il-carboni-piperidin-benzimidazole como antagonistas dos receptores v1a
GB0509276D0 (en) Synthetic receptor
IL185640A0 (en) Use of 2-anilino-3 ,4-dihydro-quinazolines as 5ht5a receptor antagonists
GB0705829D0 (en) Waste receptor
IL207438A0 (en) 2-aminoquinolines as 5-ht5a receptor antagonists
ZA200810564B (en) 2-phenyl-indoles as prostaglandin D2 receptor antagonists
IL211803A0 (en) Quinazoline derivatives as nk3 receptor antagonists